•  
  •  
  •  
  •  

2026-08-11 01:28:50

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Lemon Tree Hotels signs Second hotel in Mcleodganj
  • Axis Mutual Fund launches Axis Nifty Energy Index Fund & Axis Nifty Energy ETF NFOs offering exposure to India's evolving capital energy ecosystem
  • Websol Energy Q1FY27 Revenue up 70% YoY at Rs 373 crore; Company Prepays Entire IREDA Term Loan
  • CPPIB to Invest ₹3,000 Crore in Prestige Estates' Hospitality Arm PHVL for Up to 28% Stake
  • Krystal Integrated Services Consortium Secures ₹740 Crore Urban Wastewater Contracts in Maharashtra

Keywords Selected:  Lupin

Research

  • Lupin - Q1FY23 Result Update - Margin disappointment continues - HOLD

Stock Report

  • Lupin Announces the Approval of Sodium Zirconium Cyclosilicate for Oral Suspension in the United States
  • Lupin Announces the Approval of Diazepam Injection, USP in the United States
  • Lupin Announces U.S. FDA Approval and Launch of Sugammadex Injection
  • Lupin Spins Out Two Oncology Programs to Kaveri Therapeutics to Advance its Oncology Strategy
  • Lupin Named Among World's Most Sustainable Companies by TIME and Statista
  • Lupin Receives EIR from U.S. FDA for its Somerset Facility with VAI Classification
  • Lupin announces EMA Approval for NaMuscla® Expansion for Pediatric Indication with New Strengths
  • Lupin receives Tentative Approval from U.S. FDA for Enzalutamide Tablets
  • Lupin Launches Azilsartan Medoxomil Tablets in the United States
  • Lupin Collaborates with ERN for Luforbec® (beclometasone/formoterol) pMDI Launch in Spain
  • Lupin receives approval from U.S. FDA for Ranluspec™ (ranibizumab) Injection
  • NATCO and Lupin receive approval from U.S. FDA for Eribulin Mesylate Injection
  • Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection
  • Lupin's Ankleshwar Facility Receives EIR from U.S. FDA
  • Lupin receives China Approval for Oseltamivir Phosphate Oral Suspension
  • Lupin Receives U.S. FDA Approval for Famotidine Injection, USP
  • Lupin Ltd recommends dividend of Rs. 18
  • Lupin Ltd posts Q4FY26 consolidated PAT climbs to Rs. 1460.34 crores
  • Lupin Receives U.S. FDA Approval for Glycerol Phenylbutyrate Oral Liquid
  • Lupin Launches Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States
  • USFDA inspection at Somerset facility of Lupin Ltd
  • Lupin Pharmaceuticals, Inc, USA enters into settlement agreement with Humana Inc
  • Lupin Launches Dapagliflozin Tablets in the United States
  • Lupin announces approval of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States

Latest Post

  • Lemon Tree Hotels signs Second hotel in Mcleodganj
  • Axis Mutual Fund launches Axis Nifty Energy Index Fund & Axis Nifty Energy ETF NFOs offering exposure to India's evolving capital energy ecosystem
  • Websol Energy Q1FY27 Revenue up 70% YoY at Rs 373 crore; Company Prepays Entire IREDA Term Loan
  • CPPIB to Invest ₹3,000 Crore in Prestige Estates' Hospitality Arm PHVL for Up to 28% Stake
  • Krystal Integrated Services Consortium Secures ₹740 Crore Urban Wastewater Contracts in Maharashtra


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025